Egetis Therapeutics AB (publ) (EGTX.ST)
SEK 6.65
(-8.65%)
SEK 6.65
(-8.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -324.8 Million SEK | -61.69% |
| 2022 | -198.1 Million SEK | -87.45% |
| 2021 | -105.68 Million SEK | 40.76% |
| 2020 | -178.39 Million SEK | -167.53% |
| 2019 | -66.68 Million SEK | 27.92% |
| 2018 | -92.51 Million SEK | -5.01% |
| 2017 | -88.09 Million SEK | -129.64% |
| 2016 | -38.36 Million SEK | 12.87% |
| 2015 | -44.02 Million SEK | 9.34% |
| 2014 | -48.56 Million SEK | -86.19% |
| 2013 | -26.08 Million SEK | 26.13% |
| 2012 | -35.31 Million SEK | -3.17% |
| 2011 | -34.22 Million SEK | -800.52% |
| 2010 | -3.8 Million SEK | -182.45% |
| 2009 | -1.34 Million SEK | -139.78% |
| 2008 | -561.18 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -75.3 Million SEK | -11.74% |
| 2024 Q1 | -67.3 Million SEK | 18.52% |
| 2023 FY | -320.3 Million SEK | -61.69% |
| 2023 Q2 | -80.3 Million SEK | -7.21% |
| 2023 Q1 | -74.9 Million SEK | 4.34% |
| 2023 Q3 | -86.5 Million SEK | -7.72% |
| 2023 Q4 | -82.6 Million SEK | 4.51% |
| 2022 Q1 | -29.42 Million SEK | 9.79% |
| 2022 FY | -198.1 Million SEK | -87.45% |
| 2022 Q4 | -78.3 Million SEK | -41.34% |
| 2022 Q3 | -55.4 Million SEK | -58.37% |
| 2022 Q2 | -34.98 Million SEK | -18.88% |
| 2021 Q2 | -33.85 Million SEK | -72.63% |
| 2021 Q3 | -19.59 Million SEK | 42.14% |
| 2021 Q4 | -32.62 Million SEK | -66.51% |
| 2021 Q1 | -19.61 Million SEK | 73.28% |
| 2021 FY | -105.68 Million SEK | 40.76% |
| 2020 Q2 | -33.8 Million SEK | 27.89% |
| 2020 FY | -178.39 Million SEK | -167.53% |
| 2020 Q4 | -73.39 Million SEK | -201.77% |
| 2020 Q1 | -46.87 Million SEK | -170.58% |
| 2020 Q3 | -24.32 Million SEK | 28.05% |
| 2019 Q1 | 19.76 Million SEK | 185.81% |
| 2019 FY | -66.68 Million SEK | 27.92% |
| 2019 Q2 | -33.83 Million SEK | -271.15% |
| 2019 Q3 | -35.29 Million SEK | -4.31% |
| 2019 Q4 | -17.32 Million SEK | 50.91% |
| 2018 Q3 | -20.6 Million SEK | 32.28% |
| 2018 Q4 | -23.03 Million SEK | -11.82% |
| 2018 FY | -92.51 Million SEK | -5.01% |
| 2018 Q1 | -18.45 Million SEK | 42.63% |
| 2018 Q2 | -30.42 Million SEK | -64.84% |
| 2017 FY | -88.09 Million SEK | -129.64% |
| 2017 Q4 | -32.16 Million SEK | -17.49% |
| 2017 Q3 | -27.37 Million SEK | -68.75% |
| 2017 Q2 | -16.22 Million SEK | -31.64% |
| 2017 Q1 | -12.32 Million SEK | -7.22% |
| 2016 Q1 | -6.88 Million SEK | 22.22% |
| 2016 FY | -38.36 Million SEK | 12.87% |
| 2016 Q4 | -11.49 Million SEK | -44.34% |
| 2016 Q3 | -7.96 Million SEK | 33.75% |
| 2016 Q2 | -12.02 Million SEK | -74.65% |
| 2015 Q3 | -11.46 Million SEK | 0.24% |
| 2015 FY | -44.02 Million SEK | 9.34% |
| 2015 Q1 | -12.22 Million SEK | 30.72% |
| 2015 Q2 | -11.49 Million SEK | 5.96% |
| 2015 Q4 | -8.84 Million SEK | 22.82% |
| 2014 Q2 | -12.69 Million SEK | -84.8% |
| 2014 Q1 | -6.87 Million SEK | 3.06% |
| 2014 Q4 | -17.64 Million SEK | -54.98% |
| 2014 Q3 | -11.38 Million SEK | 10.34% |
| 2014 FY | -48.56 Million SEK | -86.19% |
| 2013 Q2 | -6.03 Million SEK | 26.12% |
| 2013 FY | -26.08 Million SEK | 26.13% |
| 2013 Q4 | -7.08 Million SEK | -47.77% |
| 2013 Q3 | -4.79 Million SEK | 20.56% |
| 2013 Q1 | -8.17 Million SEK | 5.46% |
| 2012 Q2 | -10.91 Million SEK | -15.67% |
| 2012 FY | -35.31 Million SEK | -3.17% |
| 2012 Q4 | -8.64 Million SEK | -36.78% |
| 2012 Q3 | -6.31 Million SEK | 42.1% |
| 2012 Q1 | -9.43 Million SEK | 63.84% |
| 2011 Q2 | -2.5 Million SEK | 11.71% |
| 2011 Q1 | -2.84 Million SEK | -76.55% |
| 2011 Q4 | -26.08 Million SEK | -836.38% |
| 2011 FY | -34.22 Million SEK | -800.52% |
| 2011 Q3 | -2.78 Million SEK | -11.08% |
| 2010 Q2 | -755.13 Thousand SEK | -43.45% |
| 2010 Q1 | -526.42 Thousand SEK | 0.0% |
| 2010 Q4 | -1.6 Million SEK | -76.86% |
| 2010 FY | -3.8 Million SEK | -182.45% |
| 2010 Q3 | -909.86 Thousand SEK | -20.49% |
| 2009 FY | -1.34 Million SEK | -139.78% |
| 2008 FY | -561.18 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | -30.451% |
| Ziccum AB (publ) | -21.56 Million SEK | -1406.494% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -1880.367% |
| BioArctic AB (publ) | 252.64 Million SEK | 228.562% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -38337.87% |
| Mendus AB (publ) | -100.65 Million SEK | -222.702% |
| Genovis AB (publ.) | 54.22 Million SEK | 698.997% |
| Intervacc AB (publ) | -93.57 Million SEK | -247.086% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -1993.863% |
| Active Biotech AB (publ) | -46.48 Million SEK | -598.735% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 1903.543% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | -486.102% |
| Aptahem AB (publ) | -10.1 Million SEK | -3114.327% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | -1.025% |
| Kancera AB (publ) | -65.04 Million SEK | -399.37% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | -141.277% |
| Fluicell AB (publ) | -26.87 Million SEK | -1108.378% |
| Saniona AB (publ) | -81.06 Million SEK | -300.666% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -2525.495% |
| Biovica International AB (publ) | -126.07 Million SEK | -157.629% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | -664.145% |
| AcouSort AB (publ) | -17.48 Million SEK | -1757.38% |
| Xintela AB (publ) | -57.23 Million SEK | -467.455% |
| Abliva AB (publ) | -96.54 Million SEK | -236.413% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -9166.762% |
| OncoZenge AB (publ) | -15.9 Million SEK | -1942.51% |
| Amniotics AB (publ) | -29.07 Million SEK | -1017.188% |
| 2cureX AB (publ) | -36.36 Million SEK | -793.216% |
| CombiGene AB (publ) | -36.3 Million SEK | -794.639% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -2118.579% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 15.504% |
| Camurus AB (publ) | 532.35 Million SEK | 161.012% |
| Corline Biomedical AB | -1.78 Million SEK | -18065.548% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | -79.681% |
| Isofol Medical AB (publ) | -41.68 Million SEK | -679.215% |
| I-Tech AB | 24.43 Million SEK | 1429.241% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 58.808% |
| Cyxone AB (publ) | -21.66 Million SEK | -1399.469% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | -206.516% |
| Biosergen AB | -27.26 Million SEK | -1091.271% |
| Cantargia AB (publ) | -290.01 Million SEK | -11.993% |
| NextCell Pharma AB | -43.17 Million SEK | -652.337% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | -79.681% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -1799.829% |
| Nanologica AB (publ) | -69.96 Million SEK | -364.245% |
| SynAct Pharma AB | -224.49 Million SEK | -44.68% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | -635.241% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -1255.917% |
| LIDDS AB (publ) | -40.67 Million SEK | -698.545% |
| Lipum AB (publ) | -37.25 Million SEK | -771.853% |
| BioInvent International AB (publ) | -369.94 Million SEK | 12.202% |
| Alzinova AB (publ) | -16.52 Million SEK | -1865.864% |
| Oncopeptides AB (publ) | -253.44 Million SEK | -28.153% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -4980.359% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | -182.256% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -1512.791% |
| Simris Alg AB (publ) | -36.63 Million SEK | -786.584% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | -121.605% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | -4.63% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | -192.839% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -2708.231% |